Literature DB >> 25756067

Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.

R Thakare1, I Soni1, A Dasgupta1, S Chopra2.   

Abstract

Out of a handful of new drugs currently in clinical trials for the treatment of tuberculosis, delamanid, a nitro-dihydro-imidazole derivative, has successfully emerged. Delamanid is a novel mycolic acid biosynthesis inhibitor that is equally potent against drug-sensitive as well as drug-resistant Mycobacterium tuberculosis. One of the strongest points for delamanid is its inability to be metabolized by cytochrome P450 enzymes, making it a promising candidate to be used in combination therapies for the treatment of tuberculosis and HIV. Additionally, it has successfully completed phase II efficacy trials and has received conditional marketing authorization from the European Medicines Agency. Copyright 2015 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Keywords:  Antimycobacterial; Delamanid; MDR-TB; Nitro-dihydro-imidazole derivative; Tuberculosis

Mesh：

Substances：

Year:  2015        PMID： 25756067     DOI： 10.1358/dot.2015.51.2.2245645

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN： 1699-3993            Impact factor:   2.245


  5 in total

1.  Identification of Pyrazolo[1,5-a]pyridine-3-carboxamide Diaryl Derivatives as Drug Resistant Antituberculosis Agents.

Authors:  Xianglong Hu; Baojie Wan; Yang Liu; Jiayi Shen; Scott G Franzblau; Tianyu Zhang; Ke Ding; Xiaoyun Lu
Journal:  ACS Med Chem Lett       Date:  2019-02-21       Impact factor: 4.345

2.  Selective Killing of Dormant Mycobacterium tuberculosis by Marine Natural Products.

Authors:  Carolina Rodrigues Felix; Rashmi Gupta; Sandra Geden; Jill Roberts; Priscilla Winder; Shirley A Pomponi; Maria Cristina Diaz; John K Reed; Amy E Wright; Kyle H Rohde
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 3.  Terminal Respiratory Oxidases: A Targetables Vulnerability of Mycobacterial Bioenergetics?

Authors:  Sapna Bajeli; Navin Baid; Manjot Kaur; Ganesh P Pawar; Vinod D Chaudhari; Ashwani Kumar
Journal:  Front Cell Infect Microbiol       Date:  2020-11-23       Impact factor: 5.293

4.  Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor.

Authors:  María Martínez-Hoyos; Esther Perez-Herran; Gulcin Gulten; Lourdes Encinas; Daniel Álvarez-Gómez; Emilio Alvarez; Santiago Ferrer-Bazaga; Adolfo García-Pérez; Fátima Ortega; Iñigo Angulo-Barturen; Joaquin Rullas-Trincado; Delia Blanco Ruano; Pedro Torres; Pablo Castañeda; Sophie Huss; Raquel Fernández Menéndez; Silvia González Del Valle; Lluis Ballell; David Barros; Sundip Modha; Neeraj Dhar; François Signorino-Gelo; John D McKinney; Jose Francisco García-Bustos; Jose Luis Lavandera; James C Sacchettini; M Soledad Jimenez; Nuria Martín-Casabona; Julia Castro-Pichel; Alfonso Mendoza-Losana
Journal:  EBioMedicine       Date:  2016-05-08       Impact factor: 8.143

Review 5.  Antibiotics and resistance: the two-sided coin of the mycobacterial cell wall.

Authors:  Sarah M Batt; Christopher E Burke; Alice R Moorey; Gurdyal S Besra
Journal:  Cell Surf       Date:  2020-09-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.